Literature DB >> 24487463

Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge.

Alexander M Truskinovsky1, Beatriz Lifschitz-Mercer, Bernard Czernobilsky.   

Abstract

The diagnosis of endometrial hyperplasia or carcinoma in a background of secretory endometrium can be difficult. We attempt to establish the diagnostic criteria to be used in such cases. We examined 80 cases of endometrial hyperplasia, carcinoma, and other conditions with glandular crowding arising in secretory endometrium, analyzed their morphologic features, assessed the volume percentage stroma in each case and performed Ki67 immunostaining on 27 cases. Thirteen cases each of secretory and gestational endometrium served as controls. The mean age of the patients was 45 yr. The non-neoplastic diseases included simple hyperplasia without atypia (56%), endometrial polyps (12.5%), and chronic endometritis with glandular crowding (3%). The proportion of cases with complex hyperplasia without atypia was 10%. Neoplastic diseases included atypical complex hyperplasia (12.5%) and endometrioid carcinoma (6%). The secretory changes were usually less advanced in the hyperplastic glands than in the background endometrium. The morphologic features that best distinguished hyperplasia or carcinoma from secretory endometrium included glandular crowding that stood out from the background; architectural disorder (the long axes of the glands pointing in different directions or parallel to the endometrial surface); dilated, irregularly shaped glands, including budding or branching glands and staghorn-shaped glands; stroma of a polyp; cribriform or confluent glands in cases of carcinoma; nuclear atypia in cases of atypical hyperplasia and carcinoma; and crowded nonsecretory glands. The volume percentage stroma of neoplastic lesions was less than that of non-neoplastic ones (34% vs. 61%, P=0.000001) and that of secretory endometrium (34% vs. 68%, P=0.000038). Non-neoplastic lesions did not have significantly more crowded glands than secretory endometrium (61% vs. 68%, P=0.11). Gestational endometrium had more crowded glands than non-neoplastic lesions (39% vs. 61%, P=0.000004), an approximately equal volume percentage stroma with complex hyperplasia without atypia (39% vs. 43%, P=0.51), and less crowded glands than neoplastic lesions (39% vs. 34%, P=0.03). The Ki67 index of the neoplastic lesions was higher than that of the controls, including secretory and gestational endometria (positive nuclei per 100 epithelial cells, 44.8 vs. 4.6, P=0.0004), of the non-neoplastic lesions (44.8 vs. 5.4, P=0.002) and of complex hyperplasia without atypia (44.8 vs. 9.3, P=0.007). Hyperplasia and carcinoma in secretory endometrium can be diagnosed on the basis of increased glandular crowding, architectural irregularity, nuclear atypia, and increased Ki67 index.

Entities:  

Mesh:

Year:  2014        PMID: 24487463     DOI: 10.1097/PGP.0b013e3182a2945d

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  4 in total

Review 1.  Benign endometrial proliferations mimicking malignancies: a review of problematic entities in small biopsy specimens.

Authors:  Philip Pun-Ching Ip
Journal:  Virchows Arch       Date:  2018-02-14       Impact factor: 4.064

2.  Immunohistochemical Study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study.

Authors:  R Ghalib Farhood; I Abd Ali Al-Humairi
Journal:  Arch Razi Inst       Date:  2022-02-28

3.  Clinicopathological and immunohistochemical characterization of papillary proliferation of the endometrium: A single institutional experience.

Authors:  Cheol Keun Park; Gun Yoon; Yoon Ah Cho; Hyun-Soo Kim
Journal:  Oncotarget       Date:  2016-06-28

4.  Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I.

Authors:  Gustavo Filipov Peres; Daniel Spadoto-Dias; Flávia Neves Bueloni-Dias; Nilton José Leite; Leonardo Vieira Elias; Maria Aparecida Custódio Domingues; Carlos Roberto Padovani; Rogério Dias
Journal:  Onco Targets Ther       Date:  2018-07-09       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.